A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing…

Overview of attention for article published in BMC Cancer, September 2017

Altmetric Badge

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 65 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 1 X post from an account with 2,359 followers.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal https://t.co/Tr0Wf32Mve #hvhebron #onco [Text complet] @BMC_series

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.